Abstract
Previous to the availability of antimicrobial therapy, infective endocarditis (IE) was habitually lethal. Although approximately 80 percent of patients with endocarditis currently survive their infections, one of every six patients with IE does not survive the initial hospitalization, and up to one-third of patients infected with highly virulent organisms (such as Staphylococcus aureus) may die as a direct or indirect result of their valvular infection. An unfavourable outcome in these patients can occur despite having received appropriate antimicrobial therapy in a suitable approach, and despite the expert use of modern diagnostic techniques. Our purpose is to review the main issues related to the antimicrobial therapy.
Keywords: Infective endocarditis, microorganisms, antimicrobial regimens
Infectious Disorders - Drug Targets
Title: Antibiotic Treatment in Native Valve Infective Endocarditis
Volume: 10 Issue: 1
Author(s): Rafael Garcia-Borbolla and Mariano Garcia-Borbolla
Affiliation:
Keywords: Infective endocarditis, microorganisms, antimicrobial regimens
Abstract: Previous to the availability of antimicrobial therapy, infective endocarditis (IE) was habitually lethal. Although approximately 80 percent of patients with endocarditis currently survive their infections, one of every six patients with IE does not survive the initial hospitalization, and up to one-third of patients infected with highly virulent organisms (such as Staphylococcus aureus) may die as a direct or indirect result of their valvular infection. An unfavourable outcome in these patients can occur despite having received appropriate antimicrobial therapy in a suitable approach, and despite the expert use of modern diagnostic techniques. Our purpose is to review the main issues related to the antimicrobial therapy.
Export Options
About this article
Cite this article as:
Garcia-Borbolla Rafael and Garcia-Borbolla Mariano, Antibiotic Treatment in Native Valve Infective Endocarditis, Infectious Disorders - Drug Targets 2010; 10 (1) . https://dx.doi.org/10.2174/187152610790410927
DOI https://dx.doi.org/10.2174/187152610790410927 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Toll-Like Receptors in Skin Infections and Inflammatory Diseases
Infectious Disorders - Drug Targets Production and Application of Bacteriophage and Bacteriophage-Encoded Lysins
Recent Patents on Biotechnology Pathogenic Bacterial Proteins and their Anti-Inflammatory Effects in the Eukaryotic Host
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Intracellular Life of Coxiella burnetii in Macrophages: Insight into Q Fever Immunopathology
Current Immunology Reviews (Discontinued) Development and Validation of a UV-Spectrophotometric Method for Determination of Flucloxacillin Sodium in Capsules
Current Pharmaceutical Analysis Acute Tonsillitis
Infectious Disorders - Drug Targets Preface
Recent Patents on Anti-Infective Drug Discovery The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Caenorhabditis elegans: A Model for Studying Human Pathogen Biology
Recent Patents on Biotechnology Management of Asymptomatic Severe Aortic Stenosis
Current Cardiology Reviews Continuous Infusion of Antibiotics in Critically Ill Patients
Current Clinical Pharmacology The Oral Cavity, Biofilms and Ventilator-Associated Pneumonia
Current Respiratory Medicine Reviews New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets Hybrid Viral Vectors for Vaccine and Antibody Production in Plants
Current Pharmaceutical Design Antimicrobial Development in the Era of Emerging Resistance
Mini-Reviews in Medicinal Chemistry Combating Vancomycin Resistance in Bacteria: Targeting the D-ala-D-ala Dipeptidase VanX
Infectious Disorders - Drug Targets The Co-Metabolism within the Gut-Brain Metabolic Interaction: Potential Targets for Drug Treatment and Design
CNS & Neurological Disorders - Drug Targets Valve Endothelial Cells – Not Just Any Old Endothelial Cells
Current Vascular Pharmacology 3-(1-Adamantylthio)-4-Phenylpyridine as a Potential Therapeutic for Methicillin-Resistant Staphylococcus aureus
Letters in Drug Design & Discovery Pneumonia Caused by Staphylococcus aureus
Current Respiratory Medicine Reviews